IRIS
ANDREONI, MASSIMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 87.138
AS - Asia 12.566
EU - Europa 10.995
SA - Sud America 1.910
Continente sconosciuto - Info sul continente non disponibili 1.475
AF - Africa 285
OC - Oceania 53
Totale 114.422
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 86.476
SG - Singapore 5.506
IT - Italia 2.478
CN - Cina 2.214
BR - Brasile 1.542
RU - Federazione Russa 1.434
DE - Germania 1.411
HK - Hong Kong 1.128
IE - Irlanda 1.038
UA - Ucraina 1.037
KR - Corea 943
VN - Vietnam 915
SE - Svezia 721
FR - Francia 704
BD - Bangladesh 645
GB - Regno Unito 629
FI - Finlandia 490
PL - Polonia 342
CA - Canada 337
JP - Giappone 309
IN - India 217
NL - Olanda 178
MX - Messico 115
AR - Argentina 112
ID - Indonesia 106
ZA - Sudafrica 106
AT - Austria 97
TR - Turchia 95
BE - Belgio 88
ES - Italia 80
IQ - Iraq 75
CZ - Repubblica Ceca 65
CO - Colombia 62
EC - Ecuador 62
PK - Pakistan 52
AU - Australia 49
PH - Filippine 49
CR - Costa Rica 48
JM - Giamaica 43
VE - Venezuela 41
CL - Cile 40
KG - Kirghizistan 32
MA - Marocco 31
SA - Arabia Saudita 29
UZ - Uzbekistan 25
AE - Emirati Arabi Uniti 24
CH - Svizzera 24
MY - Malesia 24
JO - Giordania 23
IL - Israele 22
EU - Europa 21
IR - Iran 21
LT - Lituania 21
HN - Honduras 20
TN - Tunisia 20
KE - Kenya 19
PY - Paraguay 19
TT - Trinidad e Tobago 19
EG - Egitto 18
GR - Grecia 18
RO - Romania 18
KZ - Kazakistan 15
TW - Taiwan 15
DZ - Algeria 14
NG - Nigeria 14
NI - Nicaragua 14
NP - Nepal 13
PE - Perù 13
AL - Albania 12
ET - Etiopia 12
CM - Camerun 11
DK - Danimarca 11
PR - Porto Rico 11
TH - Thailandia 11
HR - Croazia 10
PT - Portogallo 10
SV - El Salvador 10
UY - Uruguay 10
EE - Estonia 9
GT - Guatemala 9
SI - Slovenia 9
A2 - ???statistics.table.value.countryCode.A2??? 8
BG - Bulgaria 8
BH - Bahrain 8
OM - Oman 8
PA - Panama 8
SC - Seychelles 8
AZ - Azerbaigian 7
BA - Bosnia-Erzegovina 7
DO - Repubblica Dominicana 7
NO - Norvegia 7
AO - Angola 6
HU - Ungheria 6
LV - Lettonia 6
RS - Serbia 6
BO - Bolivia 5
BS - Bahamas 5
LB - Libano 5
AM - Armenia 4
GH - Ghana 4
Totale 112.883
Salva come PNG Salva come JPEG
Città #
Woodbridge 21.632
Wilmington 21.431
Houston 15.560
Singapore 3.217
Fairfield 2.567
Ashburn 2.434
San Jose 1.920
Chandler 1.860
Ann Arbor 1.816
Hong Kong 1.108
Seattle 1.088
Beijing 894
Dublin 871
Cambridge 870
Jacksonville 819
Council Bluffs 787
Rome 769
New York 711
Medford 650
Dearborn 568
Santa Clara 552
Los Angeles 503
The Dalles 474
Lawrence 305
Ho Chi Minh City 282
Tokyo 279
Helsinki 256
Kraków 254
Dallas 248
Milan 240
Buffalo 237
Moscow 232
Hanoi 229
Lauterbourg 211
San Diego 205
São Paulo 174
Munich 161
Menlo Park 158
Denver 154
Orem 147
Boardman 141
Zhengzhou 127
Nuremberg 117
Phoenix 117
Atlanta 116
Chicago 112
London 112
Mülheim 97
Montreal 89
North Bergen 88
Brussels 87
Toronto 83
Redondo Beach 78
Brooklyn 76
Chennai 74
Frankfurt am Main 71
Jakarta 69
Warsaw 64
Naples 61
Nanjing 59
Amsterdam 58
Johannesburg 57
Palo Alto 57
San Francisco 55
Guangzhou 51
Shanghai 51
Falls Church 50
Manchester 49
Rio de Janeiro 49
Stockholm 49
Redwood City 48
Verona 47
Norwalk 45
Dong Ket 43
Hefei 43
Hangzhou 42
San Mateo 42
Boston 41
Columbus 41
Poplar 38
Seoul 38
Belo Horizonte 37
Da Nang 37
Mountain View 37
Vienna 37
Brno 36
Mexico City 35
San José 34
Ankara 32
Bari 32
Kunming 32
Salt Lake City 32
Baghdad 30
Haiphong 30
Creede 29
Curitiba 29
Brasília 28
Lappeenranta 28
Miami 28
Mumbai 28
Totale 90.316
Salva come PNG Salva come JPEG
Nome #
Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor 593
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 593
Microbiologic characteristics and predictors of mortality in bloodstream infections in intensive care unit patients: A 1-year, large, prospective surveillance study in 5 Italian hospitals 556
The Genotypic False Positive Rate Determined by Population V3-Sequencing can Predict the Burden of X4 Quasispecies Detected by Pyrosequencing 547
18-Fluoro-2-deoxyglucose positron emission tomography-computed tomography: an additional tool in the diagnosis of prosthetic valve endocarditis. 543
Clinical predictors and microbiology of ventilator-associated pneumonia in the intensive care unit: a retrospective analysis in six Italian hospitals 536
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 529
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice 525
Human herpesvirus-8 infection in pregnancy and labor: Lack of evidence of vertical transmission 516
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 506
Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome 505
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro 503
Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression 498
Infection with human herpesvirus type 8 and Kaposi's sarcoma in a central Italian area formerly endemic for malaria 496
Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy 494
Prognostic factors of long-term CD4+ count-guided interruption of antiretroviral treatment 494
A stable CC-chemokine receptor (CCR)-5 tropic virus is correlated with the persistence of HIV RNA at less than 2.5 copies in successfully treated naïve subjects. 493
Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice 492
Comparative evaluation of subtyping tools for the surveillance of newly emerging HIV-1 strains 492
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 491
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 490
Cellular HIV-1 DNA quantitation in patients during simplification therapy with protease inhibitor-sparing regimens 487
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. 483
Optimal efficacy of interferon-free HCV retreatment after protease inhibitors failure in real life. 481
HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (< 400 HIV-RNA cp/ml) during different antiretroviral regimens 478
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 477
Multidrug resistance after lamivudine therapy for chronic hepatitis B 476
A fatal case of invasive fungal sinusitis by Scopulariopsis acremonium in a bone marrow transplant recipient 475
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. 475
Efficient and reproducible new semimicromethod for the detection and titration of HIV in human plasma 473
Dysplasia of Granulocytes in a Patient with HPV Disease, Recurrent Infections, and B Lymphopenia: A Novel Variant of WHIM Syndrome? 472
Drug-associated resistance mutations in plasma and peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected patients for whom highly active antiretroviral therapy is failing 471
HIV plasma viremia in 22 seropositive subjects [VALUTAZIONE DELLA VIREMIA PLASMATICA DA HIV IN 22 SOGGETTI SIERO-POSITIVI] 471
Specific HbsAg genetic determinants are associated with occult HBV infection in vivo and HbsAg detection 469
Decrease of replicative capacity of HIV isolates after genotypic guided change of therapy 463
Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage 462
Correlation between changes in plasma HIV RNA levels and in plasma infectivity in response to antiretroviral therapy. 462
High seroprevalence of antibodies to human herpesvirus-8 in Egyptian children: evidence of nonsexual transmission. 462
HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro 462
Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART 460
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen 460
Association between cellular human immunodeficiency virus DNA level and immunological parameters in patients with undetectable plasma viremia level during highly active antiretroviral therapy 458
Neutralizing antibodies against autologous human immunodeficiency virus type 1 isolates in patients with increasing CD4 cell counts despite incomplete virus suppression during antiretroviral treatment 457
Human herpesvirus 8 and human herpesvirus 2 infections in prison population 455
High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis 455
Specific HBSAG Genetic- Determinants are associated with occult HBV-infection in vivo and HBSAG detection 455
Reduction of IFN-gamma and IL-2 production by peripheral lymphocytes of HIV-exposed seronegative subjects 453
Failure of stavudine-lamivudine combination therapy in antiretroviral-naive patients with AZT-like HIV-1 resistance mutations 453
HIV phenotype switching during antiretroviral therapy: emergence of saquinavir-resistant strains with less cytopathogenicity 453
Cortical sources of resting state electroencephalographic rhythms probe brain function in naïve HIV individuals 452
A case of rhabdomiolysis associated with raltegravir use 451
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. 449
Viral growth assay to evaluate the replicative capacity of HIV-1 isolates 448
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group 446
ellular proviral HIV-DNA decline and viral isolation in naïve subjects with <5000 copies/ml of HIV-RNA and >500 x 10(6)/l CD4 cells treated with highly active antiretroviral therapy. 446
Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration 445
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group 445
Five human immunodeficiency virus type 1 phenotypic variants with different MT-2 cell tropisms correlate with prognostic markers of disease 445
Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV-infected over the period 2013-2016: impact on susceptibility to first-line strategies including Integrase strand-transfer inhibitors 445
Dapsone hypersensitivity syndrome complicated by Scedosporium apiospermum pneumonia in an immunocompetent patient. 444
Increase in neutralizing antibody titer against sequential autologous HIV-1 isolates after 16 weeks saquinavir (invirase) treatment 442
Correlates of HIV, HBV, and HCV infections in a prison inmate population: Results from a multicentre study in Italy 441
Infection with human herpesvirus-8 and its correlation with hepatitis B virus and hepatitis C virus markers among rural populations in Cambodia 441
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance 440
Characterization of drug resistance mutations in naive and ART-treated patients infected with HIV-1 in Yaounde, Cameroon 440
Key patterns of HBX and pre-S1/S2 mutations are involved in mechanisms underlying HBV-induced hepatocellular carcinoma in vivo 439
Interleukin-15 production by monocyte-derived dendritic cells and T cell proliferation in HIV-infected patients with discordant response to highly active antiretroviral therapy 438
Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy 438
Complication of nasal piercing by Staphylococcus aureus endocarditis: a case report and a review of literature. 437
Adherence and genotypic drug resistance mutations in HIV-1-infected patients failing current antiretroviral therapy 437
Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: A cross-sectional evaluation 436
Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens 436
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study 434
Prevalence of HHV-8 infection in Albanian adults and association with HBV and HCV 433
HIV neutralizing antibody titer during structured treatment interruption of highly active antiretroviral therapy 433
Plasma Viremia Titration and RNA Quantitation in ICD-p24 Negative HIV Type-1-Infected Patients 433
Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA 433
Once-a-day (QD) vs. Twice-daily (BID) Nevirapine as Simplification in PI-Treated Patients after 2 mos. of BID Induction 431
Prevalence and risk factors for human herpesvirus 8 infection in northern Cameroon 431
An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project 431
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 430
KSHV DNA viremia correlates with low CD4+ cell count in Italian males at the time of diagnosis of HIV infection 428
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors 428
Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity. 428
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens 428
Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages 427
Prevalence trend and correlates of HHV-8 infection in HIV-infected patients 426
Infection with human herpesvirus type 8 and human T-cell leukaemia virus type 1 among individuals participating in a case-control study in Havana City, Cuba 426
HBV, HCV, HDV AND HEV COINFECTIONS IN A COHORT OF HIV POSITIVE PATIENTS IN CAMEROON 426
Primary human herpesvirus 8 infection in immunocompetent children. 426
Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation 425
Human herpesvirus 8 cytoviraemia rebound in a patient with Kaposi's sarcoma after a short interruption of efficient antiretroviral therapy. 425
Biomarkers of monitoring and functional reserve of physiological systems over time in HIV: expert opinions for effective secondary prevention 425
Impact of pre-therapy viral load on virological response to modern first-line HAART 424
Estimating minimum adult HIV prevalence: A cross-sectional study to assess the characteristics of people living with HIV in Italy 421
Dual mixed (but not X4) tropic-HIV-1 isolates can replicate in human primary macrophages and are inhibited by CCR5- inhibitors 421
High Burden of HBV-Infection and Atypical HBV Strains among HIV-infected Cameroonians 420
High rate of HIV isolation from plasma of asymptomatic patients through polyethylene glycol (PEG) treatment 419
Time course of cellular HIV-DNA and low-level HIV viremia in HIV–HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals 419
Low testosterone levels and high estradiol to testosterone ratio are associated with hyperinflammatory state and mortality in hospitalized men with COVID-19 418
Totale 46.080
Salva come PNG Salva come JPEG
Categoria #
all - tutte 306.189
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 306.189
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.257 0 0 0 271 171 448 223 213 466 307 243 915
2022/20234.898 479 400 301 641 413 1.043 371 348 460 36 270 136
2023/20242.072 261 75 158 110 162 446 102 148 54 144 28 384
2024/20259.077 321 1.861 918 646 277 584 878 551 918 907 643 573
2025/202615.627 1.195 648 1.597 1.399 1.469 676 2.111 1.823 1.917 1.289 829 674
2026/20275.743 1.033 839 2.774 1.097 0 0 0 0 0 0 0 0
Totale 114.422